Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02569723
Recruitment Status : Active, not recruiting
First Posted : October 7, 2015
Last Update Posted : May 2, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Edward Kim, University of California, Davis

Brief Summary:
This pilot clinical trial studies how well carbon C 14 oxaliplatin microdosing assay works in predicting exposure and sensitivity to oxaliplatin-based chemotherapy in patients with colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carbon C 14 is a radioactive form of carbon, exists in nature and in the body at a low level. Microdose carbon C 14 oxaliplatin diagnostic assay may help doctors understand how well patients respond to treatment and develop individualize oxaliplatin dosing in patients with colorectal cancer.

Condition or disease Intervention/treatment Phase
Colon Adenocarcinoma Drug: Carbon C 14 Oxaliplatin Drug: Oxaliplatin Not Applicable

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate the feasibility of [14C] (carbon C 14) oxaliplatin microdose as a clinical assay to predict oxaliplatin exposure.

SECONDARY OBJECTIVES:

I. To estimate the degree to which a [14C]oxaliplatin microdose predicts the observed pharmacokinetics of standard dose oxaliplatin.

II. To validate that intrapatient variation of exposure to a [14C]oxaliplatin microdose is less than 5%.

III. To detect the levels of oxaliplatin-deoxyribonucleic acid (DNA) adducts induced by oxaliplatin microdosing in peripheral blood mononuclear cells (PBMCs), and correlate the results with patient response and progression free survival on oxaliplatin-based chemotherapy.

IV. To develop preliminary safety data of [14C]oxaliplatin microdosing for future studies.

OUTLINE:

Patients receive carbon C 14 oxaliplatin microdose intravenously (IV) over 120 minutes. Beginning not more than 4 weeks after the initial carbon C 14 oxaliplatin microdose administration, patients receive FOLFOX comprised of leucovorin calcium IV, fluorouracil IV over 2 hours (over 46-48 hours via ambulatory infusion pump on days 1 and 2), and oxaliplatin (contain carbon C 14 microdose course I only) IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of a Carbon 14 Oxaliplatin Microdosing Assay to Predict Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer
Study Start Date : October 2015
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Oxaliplatin

Arm Intervention/treatment
Experimental: carbon C 14 oxaliplatin and oxaliplatin
Patients receive carbon C 14 oxaliplatin microdose IV over 120 minutes. Beginning not more than 4 weeks after the initial carbon C 14 oxaliplatin microdose administration, patients receive FOLFOX6 comprised of leucovorin calcium IV, fluorouracil IV over 2 hours (over 46-48 hours via ambulatory infusion pump on days 1 and 2), and oxaliplatin (contain carbon C 14 microdose course I only) IV over 2 hours on day 1.
Drug: Carbon C 14 Oxaliplatin
Intravenous infusion
Other Name: [14C] Oxaliplatin

Drug: Oxaliplatin
Intravenous infusion
Other Name: Eloxatin




Primary Outcome Measures :
  1. Feasibility of 14C Oxaliplatin Microdose as a clinical assay to predict oxaliplatin exposure [ Time Frame: 0-5 minutes predose, 5, 15, and 30 minutes, and at 1, 2, 4, 8, and 24 hours after carbon C 14 oxaliplatin microdose ]
    Correlate area under curve from phase 0 microdosing with area under curve for therapeutic dose of oxaliplatin


Secondary Outcome Measures :
  1. Duration of disease control (DDC) according to RECIST 1.1 [ Time Frame: Up to 2 years ]
    Will characterize the repair of DNA adducts in PBMC, using descriptive statistics.

  2. Incidence of adverse events according to the Common Terminology Criteria for Adverse Events version 4 [ Time Frame: Up to 2 years ]
    Assess toxicity to both microdoses of carbon C 14 oxaliplatin. Toxicities potentially related to carbon C 14 oxaliplatin will be assessed from initiation of the study to at least 14 days after the administration of the FOLFOX-integrated microdose or until full recover of toxicity (whichever is longer). Safety will be assessed through summaries of adverse events and laboratory evaluations.

  3. Response rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [ Time Frame: Up to 2 years ]
    Will characterize the repair of DNA adducts in peripheral blood mononuclear cell (PBMC).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed locally advanced or metastatic colon or rectal adenocarcinoma
  • Intent to treat the patient with a leucovorin calcium, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy regimen containing fluorouracil (5-FU), leucovorin, and oxaliplatin according to clinical standard practice; the intent should be to dose oxaliplatin at 85 mg/m^2 on an every 2 week basis
  • Treatment with any additional Food and Drug Administration (FDA)-approved biologic agent (i.e. bevacizumab, cetuximab, or panitumumab) is allowed according to standard practice
  • Prior radiation or surgery is allowed, but should be finished at least 2 weeks prior to study enrollment; if a participant has prior radiation therapy, at least one measurable lesion outside of the radiation field should be available for the evaluation of response to chemotherapy
  • Any number of prior therapies other than oxaliplatin is allowed
  • Zubrod performance status equal to or less than 2 (Karnofsky equal to or greater than 50%)
  • Life expectancy of at least 3 months
  • Absolute neutrophil count greater than or equal to 1,500/microL
  • Platelets greater than or equal to 100,000/microL
  • Total bilirubin less than 3 x institutional upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase) less than or equal to 5 x ULN
  • Creatinine less than 1.5 x ULN
  • Women of child bearing potential must not be pregnant; a pre-study pregnancy test must be negative
  • Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 30 days after study participation
  • Men must agree to use adequate contraception (barrier method or abstinence) prior to study entry and for 30 days after study participation
  • Ability to understand and willing to sign a written informed consent document

Exclusion Criteria:

  • Prior treatment with oxaliplatin
  • Patients must not receive concomitant radiation
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Participants who are pregnant or nursing
  • Participants who are allergic to any platinum agent
  • Participants who have more than grade 1 peripheral neuropathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02569723


Locations
Layout table for location information
United States, California
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817
Sponsors and Collaborators
Edward Kim
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Edward Kim University of California, Davis

Layout table for additonal information
Responsible Party: Edward Kim, Principal Investigator, University of California, Davis
ClinicalTrials.gov Identifier: NCT02569723     History of Changes
Other Study ID Numbers: 736253
UCDCC#255 ( Other Identifier: UC Davis )
P30CA093373 ( U.S. NIH Grant/Contract )
UCDCC#255 ( Other Identifier: University of California Davis Comprehensive Cancer Center )
First Posted: October 7, 2015    Key Record Dates
Last Update Posted: May 2, 2019
Last Verified: April 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Oxaliplatin
Antineoplastic Agents